{"id":"gemcitabine-docetaxel-or-capecitabine","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"20-50","effect":"Anemia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-60","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"40-70","effect":"Fatigue"},{"rate":"10-30","effect":"Hand-foot syndrome"},{"rate":"10-30","effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination. Docetaxel is a taxane that stabilizes microtubules and prevents cell division. Capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into RNA and DNA. Together, these agents provide multi-modal cytotoxic activity against rapidly dividing cancer cells.","oneSentence":"This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell growth and division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:15.484Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT06976190","phase":"PHASE3","title":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2025-05-06","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":446},{"nctId":"NCT06230055","phase":"PHASE4","title":"Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-01-05","conditions":"HER2-negative Breast Cancer, Leptomeningeal Metastasis","enrollment":37},{"nctId":"NCT06118333","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":"Nasopharyngeal Carcinoma","enrollment":386},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02514681","phase":"PHASE3","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2015-08-01","conditions":"HER2-positive Locally Advanced or Metastatic Breast Cancer","enrollment":226},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT06892431","phase":"PHASE2","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy","enrollment":150},{"nctId":"NCT06629597","phase":"PHASE3","title":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-12-31","conditions":"Nasopharyngeal Carcinoma","enrollment":400},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT06719479","phase":"PHASE2, PHASE3","title":"A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).","status":"NOT_YET_RECRUITING","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2025-01-01","conditions":"NPC, HNSCC, Recurrence","enrollment":60},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT03839823","phase":"PHASE2","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-02-25","conditions":"Breast Cancer","enrollment":222},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT06156878","phase":"PHASE2","title":"PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT02611960","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-18","conditions":"Nasopharyngeal Neoplasms","enrollment":233},{"nctId":"NCT02915744","phase":"PHASE3","title":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2016-11","conditions":"Metastasis, Breast Cancer","enrollment":178},{"nctId":"NCT05549466","phase":"PHASE2","title":"Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-10-08","conditions":"Nasopharyngeal Carcinoma","enrollment":84},{"nctId":"NCT05320874","phase":"PHASE1","title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-04","conditions":"Advanced Solid Tumor","enrollment":232},{"nctId":"NCT01492101","phase":"PHASE3","title":"The BEACON Study (Breast Cancer Outcomes With NKTR-102)","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2011-12","conditions":"Locally Recurrent Breast Cancer, Metastatic Breast Cancer","enrollment":852},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT00790816","phase":"PHASE1","title":"Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Neoplasms, Breast","enrollment":500},{"nctId":"NCT00408408","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2006-11","conditions":"Breast Cancer","enrollment":1206},{"nctId":"NCT01156753","phase":"PHASE2","title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2010-07","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00868998","phase":"PHASE2","title":"GTX Regimen for Biliary Cancers","status":"TERMINATED","sponsor":"Columbia University","startDate":"2005-08","conditions":"Biliary Cancer","enrollment":4},{"nctId":"NCT00345059","phase":"PHASE3","title":"The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute, Naples","startDate":"2005-05","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":84},{"nctId":"NCT01754623","phase":"PHASE2","title":"GTX-RT in Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02","conditions":"Pancreatic Cancer","enrollment":9},{"nctId":"NCT00159471","phase":"NA","title":"Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2005-02","conditions":"Pancreatic Cancer","enrollment":1},{"nctId":"NCT00281697","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-02","conditions":"Metastatic Breast Cancer","enrollment":684},{"nctId":"NCT00476827","phase":"PHASE2","title":"A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-05","conditions":"Breast Cancer","enrollment":16},{"nctId":"NCT00246571","phase":"PHASE2","title":"Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Breast Neoplasms","enrollment":217},{"nctId":"NCT00454649","phase":"PHASE1","title":"Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":"Neoplasms","enrollment":102},{"nctId":"NCT00966706","phase":"PHASE2","title":"Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2005-06","conditions":"Pancreatic Cancer","enrollment":105},{"nctId":"NCT00191438","phase":"PHASE3","title":"Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-10","conditions":"Breast Neoplasms","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11111,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemcitabine, Docetaxel, or Capecitabine","genericName":"Gemcitabine, Docetaxel, or Capecitabine","companyName":"Shanghai Miracogen Inc.","companyId":"shanghai-miracogen-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three chemotherapy agents that work through different mechanisms to inhibit cancer cell growth and division. Used for Advanced or metastatic solid tumors (specific indication under investigation in phase 3 trial).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}